Discovery of an Allosteric Agonist for Schizophrenia Risk Gene GPR52 with Antipsychotic Activity

被引：0
|
作者：
Murphy, Ryan E. [1 ]
Felsing, Daniel E. [1 ]
Dvorak, Nolan M. [1 ]
Laezza, Fernanda [1 ]
Cunningham, Kathryn A. [1 ]
Allen, John A. [1 ]
机构：
[1] Univ Texas Med Branch, Houston, TX USA
来源：
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 2023年 / 385卷
关键词：
D O I：
10.1124/jpet.122.278870
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
537
引用
收藏
页数：1
相关论文
共 47 条
  • [1] . Discovery and Evaluation of Allosteric Agonists for the Schizophrenia Risk Gene GPR52
    Allen, John
    Murphy, Ryan
    Wang, Pingyuan
    Dvorak, Nolan M.
    Laezza, Fernanda
    Cunningham, Kathryn
    Zhou, Jia
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 388 - 388
  • [2] Orphan Receptor GPR52 Profoundly Modulates Dopamine D2 Receptor Signaling: Discovery of GPR52 Druglike Agonists With Antipsychotic Activity
    Allen, John
    Felsing, Daniel
    Murphy, Ryan
    Wang, Pingyuan
    Cunningham, Kathryn
    Zhou, Jia
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 376 - 376
  • [3] Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior
    Wang, Pingyuan
    Felsing, Daniel E.
    Chen, Haiying
    Stutz, Sonja J.
    Murphy, Ryan E.
    Cunningham, Kathryn A.
    Allen, John A.
    Zhou, Jia
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (22) : 13951 - 13972
  • [4] Targeting GPR52 for potential agonists for schizophrenia therapy: A computational drug discovery study
    Demir, Selinay
    Alparslan, Guezin Tunca
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2025, 137
  • [5] FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia
    Nishiyama, Keiji
    Suzuki, Hirobumi
    Harasawa, Toshiya
    Suzuki, Noriko
    Kurimoto, Emi
    Kawai, Takayuki
    Maruyama, Minoru
    Komatsu, Hidetoshi
    Sakuma, Kensuke
    Shimizu, Yuji
    Shimojo, Masato
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 363 (02): : 253 - 264
  • [6] The Identification of GPR52 Agonist HTL0041178, a Potential Therapy for Schizophrenia and Related Psychiatric Disorders
    Poulter, Simon
    Austin, Nigel
    Armstrong, Rachel
    Barnes, Matt
    Bucknell, Sarah Joanne
    Higueruelo, Alicia
    Banerjee, Joydeep
    Mead, Andy
    Mould, Richard
    MacSweeney, Cliona
    O'Brien, M. Alistair
    Stott, Lisa Alice
    Watson, Stephen P.
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, : 499 - 505
  • [7] The Identification of GPR52 Agonist HTL0041178, a Potential Therapy for Schizophrenia and Related Psychiatric Disorders
    Poulter, Simon
    Austin, Nigel
    Armstrong, Rachel
    Barnes, Matt
    Bucknell, Sarah Joanne
    Higueruelo, Alicia
    Banjaree, Joydeep
    Mead, Andy
    Mould, Richard
    MacSweeney, Cliona
    O'Brien, M. Alistair
    Stott, Lisa Alice
    Watson, Stephen P.
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (04): : 499 - 505
  • [8] Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease
    Komatsu, Hidetoshi
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (02) : 938 - 940
  • [9] GPR52 Agonists Represent a Novel Approach to Treat Cognitive Deficits Associated with Schizophrenia
    Grottick, Andy
    Schuelert, Niklas
    Rosenbrock, Holger
    von Heimendahl, Moritz
    Arban, Roberto
    Hobson, Scott
    BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S271 - S271
  • [10] GPR52 AGONISTS REPRESENT A NOVEL APPROACH TO TREAT UNMET MEDICAL NEED IN SCHIZOPHRENIA
    Grottick, Andrew J.
    Grayson, Ben
    Podda, Giovanni
    Idris, Nagi
    Dorner-Ciossek, Cornelia
    Neill, Joanna
    Hobson, Scott
    SCHIZOPHRENIA BULLETIN, 2018, 44 : S128 - S128
12345